Abstract:Background Pioglitazone is effective in nonalcoholic steatohepatitis (NASH), but the mechanisms of action are not completely understood. This study was designed to investigate the effects of pioglitazone on hepatic nuclear factor-kappa B (NF-kappa B) and cyclooxygenases-2 (COX-2) expression in NASH rats.Methods Thirty Sprague-Dawley male rats were randomly assigned to a control group (n=10), NASH group (n=10), and pioglitazone treatment group (n=10). Liver tissues were processed for histology by hematoxylin & eosin and Masson stained. Serum alanine aminotransferase (ALT), cholesterol, triglyceride, fasting blood glucose (FBG), fasting insulin (FINS) levels and biochemical parameters of antioxidant enzyme activities, tumor necrosis factor alpha (TNF-alpha), prostaglandin E-2 (PGE(2)) levels in serum and liver were measured. The mRNA and protein expression of peroxisome proliferator-activated receptor gamma (PPAR gamma), NF-kappa B and COX-2 were determined by real-time polymerase chain reaction, Western blotting and immunohistochemistry. One-way analysis of variance (ANOVA) and Wilcoxon's signed-rank test was used for the statistical analysis.Results There were severe steatosis, moderate inflammatory cellular infiltration and fibrosis in NASH rats. After pioglitazone treatment, steatosis, inflammation and fibrosis were significantly improved compared with the NASH group (chi(2)=20.40, P <0.001; chi(2)=20.17, P <0.001; chi(2)=13.98, P=0.002). Serum ALT, cholesterol, triglyceride, FBG, FINS levels were significantly elevated in the NASH group (P <0.05). In the NASH group, total anti-oxidation competence (T-AOC), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-PX) and malondialdehyde (MDA) levels in serum and liver were conspicuous disordered than those parameters in the control group. Meanwhile, TNF-alpha and PGE(2) levels in serum and liver were significantly increased compared with the control group. Immunohistochemistry showed NF-kappa B and COX-2 expression in liver was significantly elevated. However, PPAR gamma level was decreased in the NASH group. Real-time PCR and Western blotting revealed mRNA and protein expression of COX-2 were increased in the NASH group compared with the control group (0.57+/-0.08 vs. 2.83+/-0.24; 0.38+/-0.03 vs. 1.00+/-0.03, P <0.001 and P=0.004, respectively). After pioglitazone intervention, all of those parameters markedly improved (P <0.05 or P <0.01).Conclusion Down-regulating hepatic NF-kB and COX-2 expression, at least in part, is one of the possible therapeutic mechanisms of pioglitazone in NASH rats. Chin Med J 2012;125(13):2316-2321

A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro.

A Novel PPARα Agonist Propane-2-sulfonic Acid Octadec-9-enyl-amide Inhibits Inflammation in THP-1 Cells

Pioglitazone Ameliorates Nonalcoholic Steatohepatitis by Down-Regulating Hepatic Nuclear Factor-Kappa B and Cyclooxygenases-2 Expression in Rats.

Propane-2-sulfonic Acid Octadec-9-enyl-amide, a Novel PPARα/γ Dual Agonist, Reverses Neuroinflammation in Lipopolysaccharide-Induced Mice

The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

A Novel Dual Peroxisome Proliferator-Activated Receptors Α and Γ Agonist with Beneficial Effects on Insulin Resistance and Lipid Metabolism

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

A Novel Peroxisome Proliferator-Activated Receptor Gamma Ligand Improves Insulin Sensitivity and Promotes Browning of White Adipose Tissue in Obese Mice

A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptorγwith Excellent Effect on Insulin Resistance and Type 2 Diabetes

A pan-PPAR agonist E17241 ameliorates hyperglycemia and diabetic dyslipidemia in KKAy mice via up-regulating ABCA1 in islet, liver, and white adipose tissue

Propane-2-sulfonic Acid Octadec-9-enyl-amide, a Novel PPARα/γ Dual Agonist, Protects Against Ischemia-Induced Brain Damage in Mice by Inhibiting Inflammatory Responses.

Insulin-sensitizing Effects of a Novel Α-Methyl-α-phenoxylpropionate Derivative in Vitro

C333H,a Novel PPARα/γ Dual Agonist,has Beneficial Effects on Insulin Resistance and Lipid Metabolism

Synthesis and Investigation on the Antidiabetic Effect of 3-Aryl-1-(5-methylisox Azol-3-ylamino)-1-(4-nitrophenyl) Propan-1-one

CMHX008, a Novel Peroxisome Proliferator-Activated Receptor Γ Partial Agonist, Enhances Insulin Sensitivity in Vitro and in Vivo.

Propane-2-sulfonic acid octadec-9-enyl-amide, a novel PPARα/γ dual agonist, attenuates molecular pathological alterations in learning memory in AD mice

A Novel Agonist Of Ppar-Gamma Based On Barbituric Acid Alleviates The Development Of Non-Alcoholic Fatty Liver Disease By Regulating Adipocytokine Expression And Preventing Insulin Resistance

Experimental Study on the Glucagon-Likepeptide 1 Receptor Agonist Modulation of Insulin Resistance and Hepatic Oxidative Stress in Rats with Diabetes Mellitus Combined with Nonalcoholic Fatty Liver Disease

A Novel Agonist of PPAR-γ Based on Barbituric Acid Alleviates the Development of Non-Alcoholic Fatty Liver Disease by Regulating Adipocytokine Expression and Preventing Insulin Resistance.

N-p-coumaroyloctopamine ameliorates hepatic glucose metabolism and oxidative stress involved in a PI3K/AKT/GSK3β pathway

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold